Provided by Tiger Trade Technology Pte. Ltd.

Cogent

17.92
-0.4200-2.29%
Post-market: 17.960.0400+0.22%19:20 EDT
Volume:922.52K
Turnover:16.55M
Market Cap:897.11M
PE:-4.71
High:18.59
Open:18.07
Low:17.58
Close:18.34
52wk High:64.88
52wk Low:15.96
Shares:50.06M
Float Shares:48.25M
Volume Ratio:0.59
T/O Rate:1.91%
Dividend:3.05
Dividend Rate:17.02%
EPS(TTM):-3.8009
EPS(LYR):-3.8009
ROE:-229.15%
ROA:-2.07%
PB:-14.05
PE(LYR):-4.71

Loading ...

Cogent Communications Q4 Adjusted Gross Profit USD 112.483 Million

THOMSON REUTERS
·
Feb 20

Cogent Communications Reports Fourth Quarter 2025 and Full Year 2025 Results

THOMSON REUTERS
·
Feb 20

Analysts’ Opinions Are Mixed on These Communication Services Stocks: StarHub (OtherSRHBF) and Cogent Comms (CCOI)

TIPRANKS
·
Feb 19

Cogent Biosciences Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Feb 18

Cogent Biosciences Q4 EPS $(0.61) Misses $(0.53) Estimate

Benzinga
·
Feb 18

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire
·
Feb 17

Earning Preview: Cogent Communications Holdings’ revenue this quarter is expected to decrease by 4.17%, and institutional views are cautious

Earnings Agent
·
Feb 13

Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

GlobeNewswire
·
Feb 10

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

GlobeNewswire
·
Feb 02

Cogent Communications Holdings Inc. to Host Earnings Call and Release Operating Results

Reuters
·
Jan 29

Cogent Biosciences: Breakthrough Bezuclastinib Data, Expanding SM Franchise, and Emerging Pipeline Support Raised $54 Buy Target

TIPRANKS
·
Jan 27

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

GlobeNewswire
·
Jan 26

Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial

TIPRANKS
·
Jan 24

Cogent Biosciences Price Target Maintained With a $55.00/Share by Wedbush

Dow Jones
·
Jan 21

Cogent price target lowered to $21 from $25 at BofA

TIPRANKS
·
Jan 21

Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)

GlobeNewswire
·
Jan 20

Assessing Cogent Communications Holdings (CCOI) Valuation After Dividend Cut And Securities Investigation

Simply Wall St.
·
Jan 18

Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio

GlobeNewswire
·
Jan 12

Cogent Communications Extends CEO Contract With New Pay Terms and Equity Awards

Reuters
·
Jan 08

Cogent Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 06